By using a very sensitive and reproducible skin chamber technique we have shown that the aromatic retinoid etretinate (Ro 10‐9359) and its main metabolite (Ro 10‐1670) significantly inhibit the migration of neutrophils from the blood to tissues when applied into skin chambers (0.1 mg/ml) or when given orally (1 mg/kg/day for 8 days) to normal volunteers. This pharmacological property could be closely linked to the antipsoriatic properties of these drugs.
No takes yet. Share an insight, caveat, or question.
Dubertret et al. (1982) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: